Healthcare

This joint resolution seeks to officially disapprove a specific rule issued by the Centers for Medicare & Medicaid Services regarding the implementation of prior authorization for certain Medicare services. The proposed action would prevent the rule, known as the WISeR Model, from taking effect, thereby stopping the new requirements from being enforced. If passed, the resolution would nullify the regulation and maintain the status quo for the affected healthcare services.

This joint resolution seeks to formally disapprove a specific rule issued by the Centers for Medicare & Medicaid Services regarding the Affordable Care Act and the Basic Health Program for 2027. If passed, the measure would nullify the rule, preventing it from taking legal effect. The bill directly impacts the administration of healthcare benefits and payment parameters for the upcoming year. It is sponsored by a group of Democratic senators and is intended to halt the implementation of the agency's proposed changes.

This joint resolution seeks to reject a specific federal rule issued by the Centers for Medicare & Medicaid Services regarding the WISeR Model, which was designed to reduce wasteful spending by requiring prior authorization for select Medicare services. If passed, the measure would legally nullify the rule, preventing the Centers for Medicare & Medicaid Services from enforcing the new prior authorization requirements on healthcare providers. The bill directly affects Medicare beneficiaries and medical facilities that would otherwise have to comply with these administrative changes. By invoking the Congressional Review Act, the legislation aims to stop the implementation of the policy without altering the underlying statute governing Medicare.

SJRES 103 is a congressional disapproval resolution targeting a Department of Veterans Affairs (VA) rule on reproductive health services for veterans. The resolution, if passed, would block the VA rule from taking effect by invoking the Congressional Review Act (Chapter 8 of Title 5, U.S. Code), meaning the rule published in the Federal Register (December 31, 2025) would have no legal force. This directly affects the VA’s ability to implement new guidelines for reproductive health services at its facilities, preserving existing policies instead. The resolution does not create new policy but halts a specific administrative rule.

HJRES 144 is a congressional disapproval resolution targeting a specific rule issued by the Department of Veterans Affairs (VA) on December 31, 2025, which addressed "Reproductive Health Services" (90 Fed. Reg. 61310). This resolution directs Congress to disapprove the VA rule under Chapter 8 of Title 5, U.S. Code, meaning the rule would have no legal effect if passed. The bill directly affects the VA's implementation of reproductive health services for veterans, as it seeks to nullify the agency's existing policy. This is a procedural measure, not a substantive policy change, aimed solely at blocking the VA's rule through congressional action.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

The SAFE Drugs Act of 2026 restricts pharmacies, facilities, and physicians from compounding more than 20 times in a single month for out-of-state patients any drug that is essentially a copy of a commercially available product (e.g., containing the same active ingredient without a significant patient-specific difference). It requires these providers to submit annual reports to the federal government detailing the types of drugs compounded and the frequency for such out-of-state compounding, with reports due by year-end. The bill also mandates initial and biennial inspections for large-scale compounding facilities (those compounding over 100 times yearly) and adjusts the base fee for compounding registration to be set by the Secretary. Hospital pharmacies are exempt from the reporting requirement.

SRES 374 is a non-binding Senate resolution expressing that Secretary of Health and Human Services Robert F. Kennedy Jr. lacks the confidence of the Senate and American people to serve in his role. The resolution cites specific actions including the termination of $11 billion in public health funding, mass firings of scientists (notably eliminating 8 Offices of Minority Health), replacing all 17 members of the vaccine advisory committee (ACIP) with critics of vaccines, and dismantling programs supporting maternal health, disability services, and chronic disease research. It alleges these actions violated federal law, undermined scientific integrity, and endangered public health during a measles outbreak. The resolution calls for the Secretary’s removal but has no legal effect, as it is a symbolic statement of disapproval.

SJRES 84 is a joint resolution seeking to block a rule issued by the Centers for Medicare & Medicaid Services (CMS) under the Affordable Care Act. The rule, published in the Federal Register on June 25, 2025, aimed to improve affordability and integrity in health insurance marketplaces. If approved, this resolution would invalidate the rule under a federal disapproval process, preventing its implementation. This directly affects how health insurance plans are structured and priced for consumers using ACA marketplaces.